Charles River Laboratories International Inc has a consensus price target of $274.23, established from looking at the 56 latest analyst ratings. The last 3 analyst ratings were released from Argus Research, Evercore ISI Group, and UBS on March 18, 2024, February 15, 2024, and February 15, 2024. With an average price target of $281.67 between Argus Research, Evercore ISI Group, and UBS, there's an implied 3.96% upside for Charles River Laboratories International Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/18/2024 | CRL | Buy Now | Charles River | $270.95 | 7.03% | Argus Research | David Toung | $240 → $290 | Maintains | Buy | Get Alert |
02/15/2024 | CRL | Buy Now | Charles River | $270.95 | -2.2% | Evercore ISI Group | Ross Muken | $260 → $265 | Maintains | Outperform | Get Alert |
02/15/2024 | CRL | Buy Now | Charles River | $270.95 | 7.03% | UBS | Dan Brennan | $270 → $290 | Maintains | Buy | Get Alert |
02/15/2024 | CRL | Buy Now | Charles River | $270.95 | -7.73% | Citigroup | Patrick Donnelly | $215 → $250 | Maintains | Neutral | Get Alert |
02/15/2024 | CRL | Buy Now | Charles River | $270.95 | -1.09% | Baird | Eric Coldwell | $252 → $268 | Maintains | Outperform | Get Alert |
02/15/2024 | CRL | Buy Now | Charles River | $270.95 | 3.34% | JP Morgan | Tycho Peterson | $270 → $280 | Maintains | Overweight | Get Alert |
02/15/2024 | CRL | Buy Now | Charles River | $270.95 | — | Guggenheim | Sandy Draper | — | Downgrade | Buy → Neutral | Get Alert |
12/20/2023 | CRL | Buy Now | Charles River | $270.95 | -0.35% | JP Morgan | Tycho Peterson | $210 → $270 | Maintains | Overweight | Get Alert |
12/11/2023 | CRL | Buy Now | Charles River | $270.95 | -20.65% | Citigroup | Patrick Donnelly | $190 → $215 | Maintains | Neutral | Get Alert |
11/10/2023 | CRL | Buy Now | Charles River | $270.95 | -24.34% | Morgan Stanley | Ricky Goldwasser | $220 → $205 | Maintains | Equal-Weight | Get Alert |
11/09/2023 | CRL | Buy Now | Charles River | $270.95 | -20.65% | UBS | Dan Brennan | $250 → $215 | Maintains | Buy | Get Alert |
10/24/2023 | CRL | Buy Now | Charles River | $270.95 | -18.8% | Morgan Stanley | Ricky Goldwasser | $235 → $220 | Maintains | Equal-Weight | Get Alert |
09/25/2023 | CRL | Buy Now | Charles River | $270.95 | -22.86% | TD Cowen | Charles Rhyee | $212 → $209 | Maintains | Market Perform | Get Alert |
09/22/2023 | CRL | Buy Now | Charles River | $270.95 | -5.52% | Baird | Eric Coldwell | $267 → $256 | Maintains | Outperform | Get Alert |
09/22/2023 | CRL | Buy Now | Charles River | $270.95 | -16.96% | Guggenheim | Sandy Draper | $255 → $225 | Maintains | Buy | Get Alert |
09/22/2023 | CRL | Buy Now | Charles River | $270.95 | 1.49% | Wells Fargo | Timothy Daley | $280 → $275 | Maintains | Overweight | Get Alert |
09/13/2023 | CRL | Buy Now | Charles River | $270.95 | -21.76% | TD Cowen | Charles Rhyee | → $212 | Initiates | → Market Perform | Get Alert |
08/10/2023 | CRL | Buy Now | Charles River | $270.95 | -7.73% | JP Morgan | Tycho Peterson | $225 → $250 | Maintains | Overweight | Get Alert |
08/10/2023 | CRL | Buy Now | Charles River | $270.95 | -9.58% | B of A Securities | Derik De Bruin | $235 → $245 | Maintains | Buy | Get Alert |
The latest price target for Charles River (NYSE: CRL) was reported by Argus Research on March 18, 2024. The analyst firm set a price target for $290.00 expecting CRL to rise to within 12 months (a possible 7.03% upside). 24 analyst firms have reported ratings in the last year.
The latest analyst rating for Charles River (NYSE: CRL) was provided by Argus Research, and Charles River maintained their buy rating.
The last upgrade for Charles River Laboratories International Inc happened on February 23, 2023 when Guggenheim raised their price target to $255. Guggenheim previously had a neutral for Charles River Laboratories International Inc.
The last downgrade for Charles River Laboratories International Inc happened on February 15, 2024 when Guggenheim changed their price target from N/A to N/A for Charles River Laboratories International Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Charles River, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Charles River was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.
While ratings are subjective and will change, the latest Charles River (CRL) rating was a maintained with a price target of $240.00 to $290.00. The current price Charles River (CRL) is trading at is $270.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.